Literature DB >> 9566785

Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+CD18+ cells and CD8+CD103+ cells by multi-epitope imaging.

K Ademmer1, M Ebert, F Müller-Ostermeyer, H Friess, M W Büchler, W Schubert, P Malfertheiner.   

Abstract

Pancreatic cancer is characterized by an increasing incidence and an extremely poor prognosis. It is resistant to most of the conventional treatment modalities. Histomorphologically, it presents with a strong desmoplastic reaction around cancer cells, and lymphocytes are typically localized as aggregates in the fibrotic interstitial tissue. Using the method of multi-epitope imaging with fluorochrome-tagged specific MoAbs which allows the simultaneous localization and characterization of T cells in tissues, we studied phenotypes and distribution of tumour-infiltrating lymphocytes (TIL) in pancreatic cancer. CD3+ T cells comprised up to 90% of the tumour-infiltrating cells which were either CD4+ or CD8+, most of them being memory cells (CD45RO+). In decreasing order of frequency, T lymphocytes carried the markers for CD45RO, CD18, CD103 and TCR gammadelta. Very few natural killer cells (CD56+) were observed. Twenty percent of CD8+ were labelled with CD103. These CD8+CD103+ T cells, analogous to the gut intraepithelial lymphocytes (IEL), were found in the fibrous interstitial tissue. Furthermore, an inverse correlation was found between the expression of CD18, the beta2-integrin, which mediates adhesion of activated lymphocytes, and CD45RO in the CD8+ subset of TIL (P = 0.046). In conclusion, phenotyping of T lymphocytes in pancreatic cancer raises the possibility that pancreatic cancer cells develop several strategies to escape the T cell-induced cytolysis by (i) the aggregation of cytotoxic CD8+CD103+ T cells in the fibrous tissue distant from the tumour cells, and (ii) the presence of CD18-bearing cells which lack the expression of the activation marker CD45RO.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566785      PMCID: PMC1904939          DOI: 10.1046/j.1365-2249.1998.00546.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  The HML-1 antigen of intestinal lymphocytes is an activation antigen.

Authors:  H L Schieferdecker; R Ullrich; A N Weiss-Breckwoldt; R Schwarting; H Stein; E O Riecken; M Zeitz
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  Spontaneous cytotoxicity of human intraepithelial lymphocytes against epithelial cell tumors.

Authors:  J Taunk; A I Roberts; E C Ebert
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

4.  The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions.

Authors:  A M Krensky; F Sanchez-Madrid; E Robbins; J A Nagy; T A Springer; S J Burakoff
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

5.  The epidermal growth factor receptor in human pancreatic cancer.

Authors:  N R Lemoine; C M Hughes; C M Barton; R Poulsom; R E Jeffery; G Klöppel; P A Hall; W J Gullick
Journal:  J Pathol       Date:  1992-01       Impact factor: 7.996

6.  Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2.

Authors:  E Weidmann; L Bergmann; P Hechler; P S Mitrou
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells.

Authors:  Z A Wahab; R S Metzgar
Journal:  Pancreas       Date:  1991-05       Impact factor: 3.327

8.  Lymphocyte subsets and HLA-DR expression in normal pancreas and chronic pancreatitis.

Authors:  P Bedossa; J Bacci; G Lemaigre; E Martin
Journal:  Pancreas       Date:  1990-07       Impact factor: 3.327

9.  Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing.

Authors:  D Davignon; E Martz; T Reynolds; K Kürzinger; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors:  K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

View more
  28 in total

1.  Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.

Authors:  Mobolaji O Olurinde; Ching-Hung Shen; Adam Drake; Ailin Bai; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

2.  Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas.

Authors:  J Cresswell; H Robertson; D E Neal; T R Griffiths; J A Kirby
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 3.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

4.  TGF-β enhances the cytotoxic activity of Vδ2 T cells.

Authors:  Christian Peters; Annika Meyer; Léonce Kouakanou; Julia Feder; Tim Schricker; Marcus Lettau; Ottmar Janssen; Daniela Wesch; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2018-09-26       Impact factor: 8.110

Review 5.  Strategies for Increasing Pancreatic Tumor Immunogenicity.

Authors:  Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

Review 6.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 7.  Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.

Authors:  Alessandro Paniccia; Justin Merkow; Barish H Edil; Yuwen Zhu
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

Review 8.  Carcinogenesis of Pancreatic Ductal Adenocarcinoma.

Authors:  Peter Storz; Howard C Crawford
Journal:  Gastroenterology       Date:  2020-03-19       Impact factor: 22.682

9.  Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.

Authors:  Guang-Zhou Wu; Chun-Xia Pan; Dong Jiang; Qiang Zhang; Yin Li; Shi-Ying Zheng
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

10.  Connecting Effective Immune Response, Fluorescent Granzyme B-like Peptide, Specific Peptide Binding Patterns, Patients with Cancer and Viral Infection, in Remission, Clinical Significance, and Liquid Biopsy.

Authors:  Wai Chun Jennifer Lo; Donald Gene Luther
Journal:  J Fluoresc       Date:  2016-08-10       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.